NovoCure Statistics

Total Valuation

NovoCure has a market cap or net worth of $1.95 billion. The enterprise value is $1.72 billion.

Market Cap	1.95B
Enterprise Value	1.72B

Important Dates

The next confirmed earnings date is Thursday, July 24, 2025, before market open.

Earnings Date	Jul 24, 2025
Ex-Dividend Date	n/a

Share Statistics

NovoCure has 111.49 million shares outstanding. The number of shares has increased by 1.68% in one year.

Current Share Class	111.49M
Shares Outstanding	111.49M
Shares Change (YoY)	+1.68%
Shares Change (QoQ)	+1.67%
Owned by Insiders (%)	9.62%
Owned by Institutions (%)	85.92%
Float	100.77M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.06
Forward PS	3.01
PB Ratio	5.39
P/TBV Ratio	5.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.47, with a Debt / Equity ratio of 1.92.

Current Ratio	1.47
Quick Ratio	1.41
Debt / Equity	1.92
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-15.84

Financial Efficiency

Return on equity (ROE) is -45.52% and return on invested capital (ROIC) is -10.18%.

Return on Equity (ROE)	-45.52%
Return on Assets (ROA)	-8.64%
Return on Invested Capital (ROIC)	-10.18%
Return on Capital Employed (ROCE)	-32.42%
Revenue Per Employee	$417,817
Profits Per Employee	-$110,340
Employee Count	1,488
Asset Turnover	0.52
Inventory Turnover	3.45

Taxes

In the past 12 months, NovoCure has paid $34.37 million in taxes.

Income Tax	34.37M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.35% in the last 52 weeks. The beta is 0.72, so NovoCure's price volatility has been lower than the market average.

Beta (5Y)	0.72
52-Week Price Change	+4.35%
50-Day Moving Average	17.70
200-Day Moving Average	20.17
Relative Strength Index (RSI)	49.88
Average Volume (20 Days)	1,492,328

Short Selling Information

The latest short interest is 4.94 million, so 4.44% of the outstanding shares have been sold short.

Short Interest	4.94M
Short Previous Month	4.64M
Short % of Shares Out	4.44%
Short % of Float	4.91%
Short Ratio (days to cover)	3.33

Income Statement

In the last 12 months, NovoCure had revenue of $621.71 million and -$164.19 million in losses. Loss per share was -$1.51.

Revenue	621.71M
Gross Profit	480.70M
Operating Income	-163.88M
Pretax Income	-141.13M
Net Income	-164.19M
EBITDA	-153.51M
EBIT	-163.88M
Loss Per Share	-$1.51

Full Income Statement

Balance Sheet

The company has $929.13 million in cash and $696.73 million in debt, giving a net cash position of $232.40 million or $2.08 per share.

Cash & Cash Equivalents	929.13M
Total Debt	696.73M
Net Cash	232.40M
Net Cash Per Share	$2.08
Equity (Book Value)	361.96M
Book Value Per Share	3.25
Working Capital	346.00M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$30.46 million and capital expenditures -$41.68 million, giving a free cash flow of -$72.14 million.

Operating Cash Flow	-30.46M
Capital Expenditures	-41.68M
Free Cash Flow	-72.14M
FCF Per Share	-$0.65

Full Cash Flow Statement

Margins

Gross margin is 77.32%, with operating and profit margins of -26.36% and -26.41%.

Gross Margin	77.32%
Operating Margin	-26.36%
Pretax Margin	-20.88%
Profit Margin	-26.41%
EBITDA Margin	-24.69%
EBIT Margin	-26.36%
FCF Margin	n/a

Dividends & Yields

NovoCure does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.68%
Shareholder Yield	-1.68%
Earnings Yield	-8.41%
FCF Yield	-3.70%

Dividend Details

Analyst Forecast

The average price target for NovoCure is $32.43, which is 85.21% higher than the current price. The consensus rating is "Buy".

Price Target	$32.43
Price Target Difference	85.21%
Analyst Consensus	Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	18.85%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NovoCure has an Altman Z-Score of 0.52 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.52
Piotroski F-Score	4